



JFW
PATENTS

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Marc Belotti et al.)
Serial No. 10/796,691) Art Unit: 1614
Filed: March 8, 2004) Examiner: Not yet assigned

For: Methods and Apparatus for Creating Particle Derivatives of HDL With Reduced Lipid Content

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 16, 2004



Matthew L. Collins

Sir:


The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each Non-U.S. Patent cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,


John K. McDonald, Ph.D.
Reg. No. 42,830

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 13131-0331 (44378/293531)



AUG 18 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/20/2018 GPO:2017-093-0001-0001
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
1100 L Street, N.W., Washington, D.C. 20591-0001 (202) 707-3000

Substitute for Form ~~TRADEMARK~~

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 9

 <p>Substitute for Form TM-1</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>		Complete if Known	
		Application Number	10/796,691
		Filing Date	March 8, 2004
		First Named Inventor	Bellotti
		Group Art Unit	1614
		Examiner Name	Not yet Assigned
Sheet	1	of	9
		Attorney Docket Number	
		13131-0331 (44378/293531)	

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1	3,647,624		Evenson	03-07-1972	
	2	3,958,939		Jones	05-25-1976	
	3	3,983,008		Shinozaki et al.	09-28-1976	
	4	3,989,466		Pan	11-02-1976	
	5	4,025,423		Stonner et al.	05-24-1977	
	6	4,103,685		Lupien et al.	08-01-1978	
	7	4,124,509		Iijima et al.	11-07-1978	
	8	4,235,602		Meyer et al.	11-25-1980	
	9	4,258,010		Rozsa et al.	03-24-1981	
	10	4,350,156		Malchesky et al.	09-21-1982	
	11	4,391,711		Jackson et al.	07-05-1983	
	12	4,402,940		Nose et al.	09-16-1983	
	13	4,435,289		Breslau	03-06-1984	
	14	4,481,189		Prince	11-06-1984	
	15	4,522,809		Adamowicz et al.	06-11-1985	
	16	4,540,401		Marten	09-10-1985	
	17	4,540,573		Neurath et al.	09-10-1985	
	18	4,591,505		Prince	05-27-1986	
	19	4,613,501		Horowitz	09-23-1986	
	20	4,615,886		Purcell et al.	10-07-1986	
	21	4,643,718		Marten	02-17-1987	
	22	4,645,512		Johns	02-24-1987	
	23	4,647,280		Maaskant et al.	03-03-1987	
	24	4,648,974		Roschkopf et al.	03-10-1987	
	25	4,668,398		Silvis	05-26-1987	
	26	4,671,909		Torobin	09-09-1987	
	27	4,676,905		Nagao et al.	06-30-1987	
	28	4,680,320		Uku et al.	07-14-1987	
	29	4,696,670		Ohnishi et al.	09-29-1987	
	30	4,832,034		Pizziconi et al.	05-23-1989	
	31	4,836,928		Aoyagi et al.	06-06-1989	
	32	4,879,037		Utzinger	11-07-1989	
	33	4,895,558		Cham	01-23-1990	
	34	4,908,354		Seidel et al.	03-13-1990	
	35	4,909,940		Horowitz et al.	03-20-1990	
	36	4,909,942		Sato et al.	03-20-1990	
	37	4,923,439		Seidel et al.	05-08-1990	
	38	4,935,204		Seidel et al.	06-19-1990	
	39	4,966,709		Nose et al.	10-30-1990	

Examiner Signature _____ Date Considered _____

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO				Complete if Known	
				Application Number	10/796,691
				Filing Date	March 8, 2004
				First Named Inventor	Bellotti
				Group Art Unit	1614
				Examiner Name	Not yet Assigned
Sheet	2	of	9	Attorney Docket Number	13131-0331 (44378/293531)

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	40	5,026,479		Bikson et al.	06-25-1991	
	41	5,080,796		Nose et al.	01-14-1992	
	42	5,089,602		Isliker et al.	02-18-1992	
	43	5,112,956		Tang et al.	05-12-1992	
	44	5,116,307		Collins	05-26-1992	
	45	5,152,743		Gorsuch et al.	10-06-1992	
	46	5,187,010		Parham et al.	02-16-1993	
	47	5,203,778		Boehringer	04-20-1993	
	48	5,211,850		Shettigar et al.	05-18-1993	
	49	5,236,644		Parham et al.	08-17-1993	
	50	5,256,767		Salk et al.	10-26-1993	
	51	5,258,149		Parham et al.	11-02-1993	
	52	5,279,540		Davidson	01-18-1994	
	53	5,301,694		Raymond et al.	04-12-1994	
	54	5,354,262		Boehringer et al.	10-11-1994	
	55	5,391,143		Kensey	02-21-1995	
	56	5,393,429		Nakayama et al.	02-28-1995	
	57	5,401,415		Rauh et al.	03-28-1995	
	58	5,418,061		Parham et al.	05-23-1995	
	59	5,419,759		Naficy	05-30-1995	
	60	5,424,068		Filip	06-13-1995	
	61	5,476,715		Otto	12-19-1995	
	62	5,484,396		Naficy	01-16-1996	
	63	5,496,637		Parham et al.	03-05-1996	
	64	5,523,096		Okarma et al.	06-04-1996	
	65	5,634,893		Rishton	06-03-1997	
	66	5,637,224		Sirkar et al.	06-10-1997	
	67	5,652,339		Lerch et al.	07-29-1997	
	68	5,679,260		Boos et al.	10-21-1997	
	69	5,698,432		Oxford	12-16-1997	
	70	5,707,673		Prevost et al.	01-13-1998	
	71	5,719,194		Mann et al.	02-17-1998	
	72	5,744,038		Cham	04-28-1998	
	73	5,753,227		Strahilevitz	05-19-1998	
	74	5,853,725		Salk et al.	12-29-1998	
	75	5,855,782		Falkenhagen et al.	01-05-1999	
	76	5,858,238		McRea et al.	01-12-1999	
	77	5,877,005		Castor	03-02-1999	
	78	5,885,578		Salk et al.	03-23-1999	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 9

Complete if Known	
Application Number	10/796,691
Filing Date	March 8, 2004
First Named Inventor	Bellotti
Group Art Unit	1614
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0331 (44378/293531)

U.S. PATENT DOCUMENTS

Examiner Signature _____ Date Considered _____

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 9

Complete if Known	
Application Number	10/796,691
Filing Date	March 8, 2004
First Named Inventor	Bellotti
Group Art Unit	1614
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0331 (44378/293531)

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/796,691
		Filing Date	March 8, 2004
		First Named Inventor	Bellotti
		Group Art Unit	1614
		Examiner Name	Not yet Assigned
Sheet	5	of	9
		Attorney Docket Number	
		13131-0331 (44378/293531)	

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	128	Agnese, et al., Clinical Biochemistry, Evaluation of Four Reagents for Delipidation of Serum, 16, 98-100. (1983)	
	129	Albouz, et al., Ann. Biol. Clin., Extraction of Plasma Lipids Preserving Antigenic Properties of Proteins and Allowing Quantitation of Gangliosides by Neuraminic Acid Determination, 37, 287-290. (abstract only) (1979)	
	130	Andre et al., Journal of Virology, Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles, 76 (14), 6919-6928. (July 2002)	
	131	Badimon, et al., Laboratory Investigation, High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in Cholesterol-Fed Rabbits, 60, 455-461. (1989)	
	132	Badimon, et al., J. Clinical Investigation, Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-Fed Rabbit, 85, 1234-1241 (1990)	
	133	Barres et al., Science, Cholesterol - Making or Breaking the Synapse, 294, 1296/1297. (1996)	
	134	Bloom, et al., Clin. Biochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human serum, 14, 119-125. (abstract only) (June 1981)	
	135	Burns et al., Neurochem Res, Use of In Vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease 28, 979-86. (abstract only) (July 2003)	
	136	Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976)	
	137	Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17, 176-181. (1976)	
	138	Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of α - and β -Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976)	
	139	Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO				Complete if Known	
				Application Number	10/796,691
				Filing Date	March 8, 2004
				First Named Inventor	Bellotti
				Group Art Unit	1614
				Examiner Name	Not yet Assigned
Sheet	6	of	9	Attorney Docket Number	
13131-0331 (44378/293531)					

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	140	Cham, et al., Chem. Biol. Interactions, Importance of Apolipoproteins in Lipid Metabolism, 20, 263-277. (1978)	
	141	Cham, et al., J. Biol. Chem., In Vitro Partial Relipidation of Apolipoproteins in Plasma, 251, 6367-6371. (abstract only) (1976)	
	142	Cham, et al., Pharmacol. (Life Sci. Adv.), Lipid Apheresis in an Animal Model Causes Acute Reduction in plasma Lipid Concentrations and Mobilisation of Lipid from Liver and Aorta, 13, 25-32. (1994)	
	143	Cham, et al., J. Clin. Apheresis, Lipid Apheresis in an Animal Model Causes In Vivo Changes in Lipoprotein Electrophoretic Patterns, 11, 61-70. (1996)	
	144	Cham, et al., J. Clin. Apheresis, Lipid Apheresis: An In Vivo Application of Plasma Delipidation with Organic Solvents Resulting in Acute Transient Reduction of Circulating Plasma Lipids in Animals, 10, 61-69. (1995)	
	145	Cham, et al., Clinical Chemistry, Phospholipids in EDTA - Treated Plasma and Serum, 39, 2347-2348. (1993)	
	146	Cham, et al., 59th Congress European Atherosclerosis Society, Nice, France, Rapid Regression of Atherosclerosis by Cholesterol Apheresis - A Newly Developed Technique, 17-21. (abstract only) (May 1992)	
	147	Cham, et al., Clinica Chimica Acta, Rapid, Sensitive Method for the Separation of Free Cholesterol from Ester Cholesterol, 49, 109-113. (1973)	
	148	Collet et al., Journal of Biological Chemistry, Differential Effects of Lecithin and Cholesterol on the Immunoreactivity and Confirmation of Apolipoprotein A-I in High Density Lipoproteins, 266 (14), 9145-9152. (May 15, 1991)	
	149	Cooper, Drugs Aging, Dietary Lipids in the Aetiology of Alzheimer's Disease: Implications for Therapy , 20 (6), 399-418. (abstract only) (2003)	
	150	Deva, et al., J. Hosp. Infect., Establishment of an in-use testing method for evaluating disinfection of surgical instruments using the duck hepatitis B model , 22, 119-130. (abstract only) (June 1996)	
	151	Dwivedy, 18th Australian Atherosclerosis Society Conference, Surfers Paradise, Increase of Reverse Cholesterol Transport by Cholesterol Apheresis Regression of Atherosclerosis, 21. (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>			Complete if Known		
			Application Number	10/796,691	
			Filing Date	March 8, 2004	
			First Named Inventor	Bellotti	
			Group Art Unit	1614	
Examiner Name	Not yet Assigned				
Sheet	7	of	9	Attorney Docket Number	13131-0331 (44378/293531)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	152	Eisenhauer, et al, Klin Wochenschr (KWH), Selective Removal of Low Density Lipoproteins (LDL) by Precipitation at Low pH: First Clinical Application of the HELP System, 65, 161-168. (1987)	
	153	Fang, et al., 18th Australian Atherosclerosis Society Conference, Gold Coast, Australia, In Vivo Rapid Mobilization of Adipose Tissue by Lipid Apheresis - A Newly Developed Technique. (1992)	
	154	Feinstone, et al., Infection and Immunity, Inactivation of Hepatitis B Virus and Non-A, Non-B Hepatitis by Chloroform, 41, 816-821. (August 1983)	
	155	Golde et al., Drug Discovery Today, Cholesterol Modulation as an Emerging Strategy for the Treatment of Alzheimer's Disease, 6 (20), 1049-1055. (abstract only) (October 15, 2001)	
	156	Horowitz, et al., Blood Coagulation and Fibrinolysis, Viral safety of solvent/detergent-treated blood products, 5, S21-S28. (1994)	
	157	Innerarity, et al., Biochemistry, Enhanced Binding by Cultured Human Fibroblasts of Apo-E-Containing Lipoproteins as Compared with Low Density Lipoproteins, 17, 1440-1447. (1978)	
	158	Klimov, et al., Kardologija, Extraction of Lipids from Blood Plasma and Subsequent Introduction of Autologous Delipidized Plasma into the Body as a Possible Means to Treat Atherosclerosis [translation], 18, 23-29. (1978)	
	159	Koizumi, et al., J. Lipid Research, Behavior of Human Apolipoprotein A-1: Phospho-Lipid and apoHDL: Phospholipid Complexes In Vitro and After Injection into Rabbits, 29, 1405-1415. (1988)	
	160	Kostner, et al., XI Internet Symp. on Drugs Affecting Lipid Metabolism, Italy, Increase of APO A1 Concentration in Hypercholesterolaemic Chickens after Treatment with a Newly Developed Extracorporeal Lipid Elimination. (May 13, 1992)	
	161	Kostner, et al., European Journal of Clinical Investigation, Lecithin-cholesterol acyltransferase activity in Normocholesterolaemic and Hypercholesterolaemic Roosters: Modulation by Lipid Apheresis, 27, 212-218. (May 7, 1997)	
	162	Koudinov et al., Clin Chim Acta, Alzheimer's Amyloid Beta Interaction with Normal Human Plasma High Density Lipoprotein: Association with Apolipoprotein and Lipids, 270 (2), 75-84. (abstract only) (February 23, 1999)	
	163	Koudinov et al., Cell Biol Int., Alzheimer's Soluble Amyloid Beta Protein is Secreted by HepG2 Cells as an Apolipoprotein, 21 (5), 265-71. (abstract only) (May 1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO		Complete if Known	
		Application Number	10/796,691
		Filing Date	March 8, 2004
		First Named Inventor	Bellotti
		Group Art Unit	1614
		Examiner Name	Not yet Assigned
Sheet	8	of	9
		Attorney Docket Number	
		13131-0331 (44378/293531)	

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	164	Koudinov et al., Biochem Biophys Res Commun, Biochemical Characterization of Alzheimer's Soluble Amyloid Beta Protein in Human Cerebrospinal Fluid: Association with High Density Lipoproteins, 223 (3), 592-7. (abstract only) (June 25, 1999)	
	165	Koudinov et al., Science, Cholesterol's Role in Synapse Formation, 294, 2213. (November 9, 2001)	
	166	Koudinova et al., Soc. Neuroscience Abstract Viewer and Itinerary Planner, Amyloid Beta, Neural Lipids, Cholesterol and Alzheimer's Disease - Abstract No, 21.10. (2002)	
	167	Lipid Sciences, http://www.lipidsciences.com/technology.html , Lipid Technology, 1-4. (August 25, 2001)	
	168	Lupien, et al., Lancet (LOS), A New Approach to the Management of Familial Hypercholesterolaemia: Removal of Plasma-Cholesterol Based on the Principle of Affinity Chromatography, 1, 1261-1265. (1976)	
	169	Mauch et al., Science, CNS Synaptogenesis Promoted by Glia-Derived Cholesterol, 294, 1354-1357. (November 9, 2001)	
	170	Ngu, Medical Hypotheses, Chronic Infections from the Perspective of Evolution: a Hypothesis, 42, 81-88. (1994)	
	171	Ngu, Medical Hypotheses, Human Cancers and Viruses: A Hypothesis for Immune Destruction of Tumours Caused by Certain Enveloped Viruses Using Modified Viral Antigens, 39, 17-21. (1992)	
	172	Ngu, Medical Hypotheses, The viral envelope in the evolution of HIV: a hypothetical approach to inducing an effective immune response to the virus, 48, 517-521. (1997)	
	173	Parker, et al., Proceedings of the National Academy of Sciences, Plasma High Density Lipoprotein is Increased in Man When Low Density Lipoprotein (LDL) is Lowered by LDL-Pheresis, 83, 777-781. (1986)	
	174	Refolo et al., Soc. Neuroscience Abstracts, Cholesterol Metabolism: A Potential Target for Alzheimer's Disease Therapy, 27 (2), 1518. (abstract only) (2001)	
	175	Ryan, et al., Clinical Chemistry, An Improved Extraction Procedure for the Determination of Triglycerides and Cholesterol in Plasma or Serum, 13, 769-772. (1967)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/796,691
		Filing Date	March 8, 2004
		First Named Inventor	Bellotti
		Group Art Unit	1614
		Examiner Name	Not yet Assigned
Sheet	9	of	9
		Attorney Docket Number	
		13131-0331 (44378/293531)	

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	176	Slater, et al., J. of Lipid Research, A Comparison of Delipidated Sera Used in Studies of Sterol Synthesis by Human Mononuclear Leukocytes, 20, 413-416. (1979)	
	177	Slater, et al., Atherosclerosis, The Effect of Delipidated High Density Lipoprotein on Human Leukocyte Sterol Synthesis, 35, 41-49. (1980)	
	178	Thompson, et al., Lancet (LOS), Plasma Exchange in the Management of Homozygous Familial Hypercholesterolemia, 1, 1208-1211. (1975)	
	179	Williams, et al., Proc. Natl. Acad. Sci. USA, Low Density Lipoprotein Receptor-Independent Hepatic Uptake of a Synthetic, Cholesterol-Scavenging Lipoprotein: Implications for the Treatment of Receptor-Deficient Atherosclerosis, 85, 242-246. (1988)	
	180	Wong, et al, Journal of Lipid Research, Retention of gangliosides in serum delipidated by diisopropyl ether-1-butanol extraction, 24, 666-669. (1983)	
	181	Yokoyama, et al., Arteriosclerosis, Selective Removal of Low Density Lipoprotein by Plasmapheresis in Familial Hypercholesterolemia, 5, 613-622. (1985)	
	182	Yoshidome et al., Artif Organs, Serum Amyloid A and P Protein Levels are Lowered by Dextran Sulfate Cellulose Low-Density Lipoprotein Apheresis, 22 (2), 144-148. (1998)	
	183	Zetia, http://www.zetia.com/ezetimibe/zetia/hcp/product_highlights/index.jsp , Zetia (ezetimibe), 1-2. (August 18, 2003)	
	184	Zetia, http://www.zetia.com/ezetimibe/zetia.hcp/mechanism_of_action/index.jsp , Zetia: Compliments Statin with a Unique Mechanism, 1-2. (August 18, 2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.